Click image to enlarge.
Source: Bloomberg
Valeant Pharmaceuticals (VRX) is trading around $80, down almost 70% from its August high. Here's the current breakdown of the 25 Wall Street analysts covering the stock:
- 65% currently rate VRX a Buy
- The average analyst price target is $199
- That implies approximately 150% upside
No words.
Reality check. Our Healthcare analysts just released a research note to institutional subscribers outlining why we think shares are worth $20. To be clear, we’ve long been skeptical.
CLICK HERE to read their original Short thesis on VRX from 7/22/14.
